Home / Market News / $ALLO

$ALLO news and market catalysts

The 4 most recent market catalysts affecting $ALLO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 0 high impact 0 bullish 0 bearish Biotechnology
Nov 5, 2026 Corporate Catalyst Neutral Impact 65
Allogene Therapeutics Reports Financial Results for Third Quarter 2026
Allogene Therapeutics (ALLO) filed an 8-K to announce its third-quarter 2026 financial results and provide corporate updates on its AlloCAR T product pipeline. This is a routine qu…
Oct 29, 2026 Corporate Catalyst Neutral Impact 65
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
Allogene Therapeutics is announcing two key investor events in November 2026: its Q3 2026 earnings call and a webinar to present preliminary Phase 1 data for ALLO-329 in autoimmune…
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
Allogene Therapeutics EVP And CFO Geoffrey Parker To Retire, Effective November 6
Allogene Therapeutics (ALLO) announced that its EVP and CFO, Geoffrey Parker, will retire on November 6, 2026. This is a significant executive change, as the CFO plays a crucial ro…
Aug 12, 2026 Corporate Catalyst Neutral Impact 55
Allogene Therapeutics Files Prospectus For $500M Offering
Allogene Therapeutics filed an S-3 shelf registration statement, allowing them to offer and sell up to $500 million in various securities (common stock, preferred stock, debt secur…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.